Deriglidole

SKU: orb1709898

Description

Deriglidole (SL 86-0715) is a selective alpha2-adrenergic receptor antagonist. It has been utilized in research to investigate adrenergic signaling pathways in both in vitro and in vivo models, particularly in studies of cardiovascular and autonomic nervous system function.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 122830-14-2
• MW: 255.36
• Purity: 99.03% (May vary between batches)
• Formula: C₁₆H₂₁N₃
• SMILES: C(CC)C1(N2C=3C(C1)=CC=CC3CC2)C=4NCCN4
• Target: Adrenergic Receptor
• Solubility: DMSO:32.5 mg/mL (127.27 mM)

Bioactivity

• In Vivo:
  In mouse pancreatic beta-cells that both deriglidole and SL86.0714 inhibit ATP-sensitive K+ channel with similar potency whereas alpha2-adrenoceptors are blocked only by deriglidole. In diabetic rats, SL84.0418 and deriglidole (10 mg/kg i.p.) fully normalized glucose tolerance whereas SL86.0714 and tolbutamide only slightly improved it. Five min after deriglidole administration in mice a marked and short lasting rise in insulin levels was observed, followed by a progressive reduction of glycemia.
• In Vitro:
  Deriglidole is a specific inhibitor of α2-receptors. Deriglidole inhibits the binding of [3H] clonidine and [3H] imidazole x, while showing no inhibitory effect on the binding of [3H] prazosin to rat cortex and human platelet α2-adrenergic receptors. Furthermore, it demonstrates greater effectiveness than idazolide in selectively targeting peripheral receptors.

Storage & Handling

• Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Deriglidole, Adrenergic Receptor, AdrenergicReceptor, SL 86-0715, α2 receptor

Compound Identifiers

PubChem CID

65945